ClinicalTrials.gg
RecruitingNCT06624839PROTECTUpdated Aug 5, 2026

Evaluating Gardasil HPV Vaccine Humoral and Cellular Immune Responses in People With and Without HIV

A Phase 2 interventional study of Human papillomavirus (HPV) vaccine, 9-valent in Human Papilloma Virus, Anal Dysplasia and HIV, sponsored by University of Maryland, Baltimore. Recruiting at 2 sites in United States. Open to male participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Papilloma with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Papilloma · United States.

Planned enrollment
22nd of 39
120 · median 155
Started
2025
with 1 other
Phase 2
7 of 51
3 open now
Primary completion
2027-01
later than 5 of 12 live
Registered
45th of 51
by date

Among the 51 studies in Papilloma with a site in United States, this one is the 22nd largest by planned enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 45th registered.

Papilloma

89 studies on the registry are indexed under Papilloma; 20 are open to participants now.

Browse Papilloma studies →

Open to participants now

9 of the 51 studies in Papilloma with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Papilloma studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Papilloma with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1 month following the final vaccine dose).

Read the detailed description

This will be a phase 2, open-label study to assess the humoral and cellular immune response to the FDA-approved 9-valent HPV recombinant vaccine in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). At baseline, BM-EABE with HIV, HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) will provide blood samples and anal swabs for evaluation of HPV immunity, anal HPV and anal dysplasia. All participants will undergo a 3-dose vaccine series of the Gardasil vaccine (at Day 0, Month 2 and Month 6). Participants will then return one month after completion of third vaccine (Month 7) to provide repeat blood samples and anal swabs. Samples will be compared pre and post vaccination and in-between participants based on HIV and exposure to androgen blockers or estrogen (EABE).

Any participant with human papillomavirus 16 (HPV16) and/or anal dysplasia on anal cytology at any point will be referred to high-resolution anoscopy (HRA) for clinical management. Anal biopsies will be procured from different pathology laboratories - after clinical evaluation has been complete - for research analysis, including confocal microscopy. Those who had anal dysplasia at study entry will undergo repeat HRA, as clinically indicated, and will have an optional study visit following their repeat HRA to provide blood draw and anal swabs.

03

Conditions studied

  • Human Papilloma Virus
  • Anal Dysplasia
  • HIV

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old or older and 70 years old or younger
  • Able to provide
  • Denies history of prior HPV vaccination with Gardasil9 (receipt of HPV vaccination other than Gardasil9 such as the bivalent or the quadrivalent HPV vaccine will be allowed) or unsure of vaccination status and born before 2003
  • Born Male

For Test group: -positive people born male with current or past exposure to androgen blockers or estrogen (BM-EABE)

  • Living with HIV
  • Current or past exposure to androgen blockers or estradiol

For Control group: HIV-negative Control

  • HIV negative
  • Either: Current or past exposure to androgen blockers or estradiol; no current or past exposure to androgen blockers or estradiol AND had sex with a person with a penis in the last year

Exclusion criteria

Exclusion Criteria:

  • Younger than 18 years old or older than 70 years old.
  • Self-reported or documented history of nine-valent HPV vaccine or unsure of vaccination status and born after 2003.
  • Born female
  • History of , including severe reactions to yeast or other component of the vaccine.
  • Any condition requiring systemic chemotherapy or immunomodulant affecting antibody responses (i.e., rituximab, ibrutinib etc.), intravenous or subcutaneous immunoglobulin supplementation, radiation therapy, or immunomodulatory treatment within the previous 6 months (presence of precancerous lesions is not exclusionary).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    People born male with current or past exposure to androgen blockers or estrogen (BM-EABE)

    One dose of human papillomavirus (HPV) vaccine, 9-valent (Gardasil9) will be administered on Day 0, Month 2, and Month 6

    Biological: Human papillomavirus (HPV) vaccine, 9-valent

  • Active comparator
    HIV Negative BM-EABE or HIV Negative men who had sex with a person with a penis (MSPP)

    One dose of human papillomavirus (HPV) vaccine, 9-valent (Gardasil9) will be administered on Day 0, Month 2, and Month 6

    Biological: Human papillomavirus (HPV) vaccine, 9-valent

Interventions

06

What researchers measure

Primary outcomes

  1. Immunogenicity of the human papillomavirus (HPV) vaccine in BM-EABE (people born male with current or past exposure to androgen blockers or estrogen (BM-EABE) with and without HIV

    Proportion of BM-EABE who become seropositive or have an increase in their GMT by \>25% to at least 1 homologous HPV vaccine genotype at 1 month following the 3rd dose of the vaccine.

    Time frame: 7 months post 1st vaccine dose

Secondary outcomes

  1. Compare the humoral immune response to Gardasil9 between HIV positive BM-EABE and HIV negative controls

    The difference between GMT titers against the 9-specific HPV types included in Gardasil between HIV positive BM-EABE and HIV negative controls.

    Time frame: 7 months post 1st vaccine dose

  2. Compare the humoral immune response to Gardasil9 between BM-EABE (regardless of HIV status) and BM without EABE (people born male without current or past exposure to androgen blockers or estrogen)

    The difference between GMT titers against the 9-specific HPV types included in Gardasil between BM-EABE and BM without EABE

    Time frame: 7 months post 1st vaccine dose

  3. Evaluate the systemic HPV T-cell immune response to Gardasil9 in HIV positive BM-EABE and HIV negative controls.

    A comprehensive assessment of HPV-specific T cell responses will be conducted with antigen stimulation of peripheral blood mononuclear cells (PBMCs) with virion-like protein (VLP) included in Gardasil 9. The proportion of proliferating T- cells, expressing activation-induced markers (AIM+) and IFN-gamma and TNF-alpha secreting T-cells will be evaluated by flow-cytometric assays; in addition the expression of exhaustion markers, perforin/granzyme B and skin- and gut-homing receptors, as well as the transcriptional analysis of T cells proliferating upon HPV antigenic stimulation will be assessed. This response will be assessed in HIV positive BM-EABE and HIV negative controls (BM-EABE and BM without EABE).

    Time frame: 7 months post 1st vaccine dose

  4. Compare systemic HPV T-cell immune response to Gardasil9 between HIV positive BM-EABE and HIV negative controls.

    The proportion of proliferating T- cells, expressing activation-induced markers (AIM+) and IFN-gamma and TNF-alpha secreting T-cells, the expression of exhaustion markers, perforin/granzyme B and skin- and gut-homing receptors and the transcriptional analysis of T cells proliferating upon HPV antigenic stimulation will be compared between: HIV positive BM-EABE and HIV negative controls; BM-EABE and BM without EABE

    Time frame: 7 months post 1st vaccine dose

  5. Compare systemic HPV T-cell immune response to Gardasil9 between BM-EABE (regardless of HIV status) and BM without EABE.

    The proportion of proliferating T- cells, expressing activation-induced markers (AIM+) and IFN-gamma and TNF-alpha secreting T-cells, the expression of exhaustion markers, perforin/granzyme B and skin- and gut-homing receptors and the transcriptional analysis of T cells proliferating upon HPV antigenic stimulation will be compared in BM-EABE and BM without EABE.

    Time frame: 7 months post 1st vaccine dose

  6. Evaluate the impact of HPV vaccination on HIV reservoir in CD4 T cells of BM-EABE with HIV.

    Distribution and density of mucosal immune cells (CD4+ and CD8+ T-cells, B/plasma cells, Dendritic/Langerhans cells, Natural killer (NK) cells, and macrophages) as seen on confocal microscopy from anal biopsies from HIV positive BM-EABE and HIV negative controls before Gardasil vaccination. Difference in distribution of mucosal immune cells as seen on confocal microscopy from anal biopsies after Gardasil.

    Time frame: Before vaccination, 7 months post 1st dose

  7. Compare humoral immune response to Gardasil9 between different subset populations from PROTECT (HIV positive BM-EABE , HIV negative BM-EABE , and HIV negative MSPP), to age-matched historical controls.

    The difference between GMT titers against the 9-specific HPV types included in Gardasil between subset of populations from PROTECT (HIV positive BM-EABE, HIV negative BM-EABE, men who have sex with a person with a penis (MSPP)) and historical controls from stored samples at the NIH

    Time frame: 7 months post 1st vaccine dose

07

Study locations

1 of 2 sites recruiting
  • RIIS Clinic at HIPS
    Washington D.C., District of Columbia 20002, United States
    Not yet recruiting
  • RIIS Clinic at Baltimore Safe Haven
    Baltimore, Maryland 21201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The principal investigator will share de-identified data with approved researchers at the time of publication or shortly afterwards.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data will be made available at the time of publication or shortly following publication, and will be available indefinitely.

Access criteria: The criteria will be determined by the Principal Investigator

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2024
First posted
Oct 3, 2024
StartActual
Mar 15, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06624839
Responsible party
Sponsor
First posted
Oct 3, 2024
Start date
Mar 15, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Omar Harfouch, MD
Contact
oharfouch@ihv.umaryland.edu
410-706-1372
Onyinyechi Ogbumbadiugha-Weekes, MPH
Contact
oogbumbadiugha@ihv.umaryland.edu
443-635-4943
Omar Harfouch, MD
principal investigator · University of Maryland, Baltimore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent

Start the discussion